AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst ...

The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past ...

AbbVie reported revenues of $14.46 billion in the last reported quarter, representing a year-over-year change of +3.8%. EPS of $3 for the same period compares with $2.95 a year ago.

AbbVie is expected to post earnings of $2.90 per share for the current quarter, representing a year-over-year change of +3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

This was the stock's third consecutive day of losses.

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...